Measurable residual disease (MRD) can be detected using two main techniques: next-generation sequencing and flow cytometry. Here, Bruno Paiva, PhD, of the University of Navarra, Navarra, Spain, weighs up the different techniques at the 23rd congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. Dr Paiva discusses some of the limitations facing clinicians in accessing each technique, and concludes that the technique is less important than the use of rigorously standardized and validated methods to collect data.
